Literature DB >> 17392171

A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice.

Wan-Lin Yang1, Kathy Qi Cai, Jennifer L Smedberg, Elizabeth R Smith, Andres Klein-Szanto, Thomas C Hamilton, Xiang-Xi Xu.   

Abstract

Menopausal ovaries undergo morphological changes, known as ovarian aging, which are implicated in the high incidence of ovarian cancer occurring during the perimenopausal and immediate postmenopausal periods. The germ cell-deficient Wv mice recapitulate these postmenopausal alterations in ovarian morphology and develop tubular adenomas. We demonstrate that a reduction of cyclooxygenase 2 gene dosage rescued the ovarian aging phenotype of the Wv mice, whereas homozygous deletion was accompanied by a compensatory increase in ovarian cyclooxygenase 1 expression and prostaglandin E(2) synthesis. Cyclooxygenase inhibitors also reduced the tumor phenotype in a preliminary study. These findings suggest that increased cyclooxygenase activity contributes to the preneoplastic morphological changes of the ovarian surface epithelium, which can be reversed by a reduction of gene dosage achieved by either genetic or pharmacological approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392171      PMCID: PMC1829465          DOI: 10.2353/ajpath.2007.060769

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

Review 1.  Why there are two cyclooxygenase isozymes.

Authors:  W L Smith; R Langenbach
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 2.  The role of cyclooxygenases in inflammation, cancer, and development.

Authors:  C S Williams; M Mann; R N DuBois
Journal:  Oncogene       Date:  1999-12-20       Impact factor: 9.867

Review 3.  Ovulation: new dimensions and new regulators of the inflammatory-like response.

Authors:  JoAnne S Richards; Darryl L Russell; Scott Ochsner; Lawrence L Espey
Journal:  Annu Rev Physiol       Date:  2002       Impact factor: 19.318

4.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

Authors:  G Steinbach; P M Lynch; R K Phillips; M H Wallace; E Hawk; G B Gordon; N Wakabayashi; B Saunders; Y Shen; T Fujimura; L K Su; B Levin; L Godio; S Patterson; M A Rodriguez-Bigas; S L Jester; K L King; M Schumacher; J Abbruzzese; R N DuBois; W N Hittelman; S Zimmerman; J W Sherman; G Kelloff
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

5.  Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice.

Authors:  J Reese; X Zhao; W G Ma; N Brown; T J Maziasz; S K Dey
Journal:  Endocrinology       Date:  2001-07       Impact factor: 4.736

6.  Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice.

Authors:  P C Chulada; M B Thompson; J F Mahler; C M Doyle; B W Gaul; C Lee; H F Tiano; S G Morham; O Smithies; R Langenbach
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

7.  Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.

Authors:  G Lal; C Ash; K Hay; M Redston; E Kwong; B Hancock; T Mak; S Kargman; J F Evans; S Gallinger
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

8.  Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations.

Authors:  Kathy Qi Cai; Andres Klein-Szanto; Devarajan Karthik; Mitchell Edelson; Mary B Daly; Robert F Ozols; Henry T Lynch; Andrew K Godwin; Xiang-Xi Xu
Journal:  Gynecol Oncol       Date:  2006-05-12       Impact factor: 5.482

Review 9.  Cyclooxygenase 2: a molecular target for cancer prevention and treatment.

Authors:  Kotha Subbaramaiah; Andrew J Dannenberg
Journal:  Trends Pharmacol Sci       Date:  2003-02       Impact factor: 14.819

10.  Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.

Authors:  Sandra Orsulic; Yi Li; Robert A Soslow; Lynn A Vitale-Cross; J Silvio Gutkind; Harold E Varmus
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

View more
  12 in total

1.  Follicle Depletion Provides a Permissive Environment for Ovarian Carcinogenesis.

Authors:  Ying Wang; Kathy Qi Cai; Elizabeth R Smith; Toni M Yeasky; Robert Moore; Parvin Ganjei-Azar; Andres J Klein-Szanto; Andrew K Godwin; Thomas C Hamilton; Xiang-Xi Xu
Journal:  Mol Cell Biol       Date:  2016-08-26       Impact factor: 4.272

2.  Charged-Iron-Particles Found in Galactic Cosmic Rays are Potent Inducers of Epithelial Ovarian Tumors.

Authors:  Birendra Mishra; Gregory W Lawson; Ryan Ripperdan; Laura Ortiz; Ulrike Luderer
Journal:  Radiat Res       Date:  2018-05-21       Impact factor: 2.841

3.  White spotting variant mouse as an experimental model for ovarian aging and menopausal biology.

Authors:  Elizabeth R Smith; Toni Yeasky; Jain Qin Wei; Roberto A Miki; Kathy Q Cai; Jennifer L Smedberg; Wan-Lin Yang; Xiang-Xi Xu
Journal:  Menopause       Date:  2012-05       Impact factor: 2.953

4.  Sex Differences in Embryonic Gonad Transcriptomes and Benzo[a]pyrene Metabolite Levels After Transplacental Exposure.

Authors:  Jinhwan Lim; Aramandla Ramesh; Toshi Shioda; Kathleen Leon Parada; Ulrike Luderer
Journal:  Endocrinology       Date:  2022-01-01       Impact factor: 4.736

5.  Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.

Authors:  Callinice D Capo-chichi; Toni M Yeasky; Joshua F Heiber; Ying Wang; Glen N Barber; Xiang-Xi Xu
Journal:  Gynecol Oncol       Date:  2009-11-22       Impact factor: 5.482

6.  Cyclooxygenase-1 inhibition prolongs postnatal ovarian follicle lifespan in mice.

Authors:  Elizabeth R Smith; Wan-Lin Yang; Toni Yeasky; Jennifer Smedberg; Kathy Q Cai; Xiang-Xi Xu
Journal:  Biol Reprod       Date:  2013-10-31       Impact factor: 4.285

7.  Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion.

Authors:  Elizabeth R Smith; Xiang-Xi Xu
Journal:  Lancet Oncol       Date:  2008-11       Impact factor: 41.316

8.  Glutathione-deficient mice have increased sensitivity to transplacental benzo[a]pyrene-induced premature ovarian failure and ovarian tumorigenesis.

Authors:  Jinhwan Lim; Gregory W Lawson; Brooke N Nakamura; Laura Ortiz; Jin A Hur; Terrance J Kavanagh; Ulrike Luderer
Journal:  Cancer Res       Date:  2012-11-07       Impact factor: 12.701

Review 9.  Development of a mouse model of menopausal ovarian cancer.

Authors:  Elizabeth R Smith; Ying Wang; Xiang-Xi Xu
Journal:  Front Oncol       Date:  2014-02-26       Impact factor: 6.244

Review 10.  Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.

Authors:  Joshua F Heiber; Xiang-Xi Xu; Glen N Barber
Journal:  Chin J Cancer       Date:  2011-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.